Method for reducing platelet aggregation

Details Method for reducing platelet aggregation Method for reducing platelet aggregation

1993-04-22

1995-03-28

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ortho-hydroxybenzoic acid or derivative doai

514494, 514557, 514822, A61K 3160, A61K 31315, A61K 3119

Patent

active

054017300

ABSTRACT:
Patients having a predisposition for thrombus formation are effectively treated with compositions of acetylsalicylic acid, citric acid, thiamine and/or a zinc salt. The combination of aspirin and citric acid has been found to be significantly more effective in inhibiting platelet aggregability than aspirin alone, and thiamine contributes to the reduction in thrombotic potential by reducing plasma fibrinogen levels. Accordingly, new methods and compositions are disclosed for reducing the thrombotic potential of human or animal subjects, such as in the prophylaxis or treatment of atherosclerosis, vascular surgery patients or other cardiovascular diseases.

REFERENCES:
patent: 3842169 (1974-10-01), Schneyer
patent: 4080446 (1978-03-01), Leopold et al.
patent: 4080447 (1978-03-01), Amselem
patent: 4734405 (1988-03-01), Koenig
The Merck Index, abstracts Nos. 863 and 2297.
Handbook of Nonprescription Drugs, p. 129.
Bekheet, I. A., "The Effect of Some Inhibitors on the Activity of Lipoxygenase", Alex. Sci. Exch. 7(3):389-398, 1986.
Von S. Drescher, "On the Inhibitory Effect of Metal Salts on Experimental Vascular Calcinosis", Beitr. path. Anat. 130:74-92, 1969.
Greaves, M. W. and A. W. Skillen, "Effects of Long-Continued Ingestion of Zinc Sulphate in Patents with Venous Leg Ulceration", The Lancet, Oct. 31, 1970, 889-891, 1970.
Kaplan, S. et al., "A New Combination Therapy for Selective and Prolonged Antiplatelet Effect: Results in the Dog", Stroke 17(3):450-454, 1986.
Kaplan, S. et al., "The effect of Predetermined thrombotic potential of the recipient on small-caliber graft performance", J. Vasc. Surg. 3(2):311-321, 1986.
McBean, L. D. et al., "Serum Zinc and Alpha.sub.2 -Macroglobulin Concentration in Myocardial Infarction, Decubitus Ulcer, Multiple Myeloma, Prostatic Carcinoma, Down's Syncrome and Nephrotic Syndrome", Clinica Chimica Acta 50:43-51, 1974.
Weiss, H. J. et al., "Effect of Aspirin and Dipyridamole on the Interaction of Human Platelets with Sub-Endothelium: Studies Using Citrated and Native Blood", Thrombosis and Haemostasis 45(2):136-141, 1981.
Kannel, W. B. et al., "Fibrinogen and Risk of Cardiovascular Disease", JAMA 258(9):1183-1186, 1987.
Stone, M. C. and J. M. Thorp, "Plasma fibrinogen--a major coronary risk factor", J. Roy. Coll. Gen. Pract. 35(281), 565-569, 1985.
Wilhelmsen, L. et al., "Fibrinogen as a Risk Factor for Stroke and Myocardial Infarction", N. Engl. J. Med. 311(8):501-505, 1984.
Apprill, P. G. et al., "Ancrod decreases the frequency of cyclic flow variations and causes thrombolysis following acute coronary thrombosis", Amer. Heart J. 113(4):898-906, 1986.
Hossmann, V. et al., "Controlled Trail of Ancrod in Ischemic Stroke", Arch. Neurol. 40:803-808, 1983.

Affiliated with

Also associated with

Rating

Method for reducing platelet aggregation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for reducing platelet aggregation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing platelet aggregation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2250636